Acadia Pharma

Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study
Reuters
Mon, 03/11/24 - 04:56 pm
Acadia Pharma
antipsychotics
clinical trials
schizophrenia
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Mon, 10/9/23 - 11:10 am
Ipsen
Sohonos
Sarepta Therapeutics
Elevidys
Biogen
Qalsody
Eisai
Aduhelm
Jazz Pharma
PharmaMar
Zepzelca
Acadia Pharma
Nuplazid
Schizophrenia: Four major clinical trials to watch in 2023
Clinical Trials Arena
Thu, 04/13/23 - 10:08 pm
clinical trials
schizophrenia
Reviva
brilaroxazine
Newron
evenamide
Sunovion
ulotaront
Acadia Pharma
pimavanserin
Go or no go? J&J’s bispecific FDA first
EP Vantage
Thu, 07/28/22 - 11:04 am
JNJ
Amicus Therapeutics
Acadia Pharma
Bluebird Bio
FDA
Go or no go? The FDA’s Amylyx dilemma
EP Vantage
Tue, 05/31/22 - 10:29 am
FDA
Amylyx
AMX0035
ALS
COVID-19
vaccines
Novavax
Moderna Therapeutics
Pfizer
Acadia Pharma
Bluebird Bio
Acadia closer to bringing first Rett syndrome drug to market
Pharmaforum
Wed, 12/8/21 - 10:33 am
Acadia Pharma
trofinetide
clinical trials
Rett Syndrome
Acadia fails in attempt to expand use of antipsychotic to treat patients with depression
Stat
Mon, 07/20/20 - 11:54 pm
Acadia Pharma
clinical trials
major depression
Nuplazid
major depressive disorder
antipsychotics
Fresh off positive Nuplazid data, Acadia adds new clinical drug from Vanderbilt in milestone-heavy deal
Endpoints
Fri, 05/8/20 - 10:43 am
Acadia Pharma
Vanderbilt
Nuplazid
drug development
Alzheimer's disease
Parkinson's Disease